Dr. Mann Fung is the Chief Executive Officer of Tavotek Biotherapeutics. He has nearly 30 years of experience in the Regulatory, Pharmaceutical and Finance Industries including FDA, Big Pharma, and Venture Capital. Prior to joining Tavotek in 2019, Dr. Fung was a Venture Partner at Fidelity Eight Roads Ventures as well as a clinical consultant for BioMotiv Capital. He is currently an Investment Committee member of the Apricot-Sanhe Entrepreneur Fund and a Scientific Advisory Board member of Virogin Biotech and YiSheng Biopharma.

Dr. Mark Chiu is the President of R&D as well as Chief Scientific Officer at Tavotek Biotherapeutics. He has nearly 35 years of experience in new drug discovery for AbbVie/Abbott Laboratories and Janssen. Prior to joining Tavotek, Dr. Chiu was the Head of the Process Analytical Sciences at Biotherapeutics Development and Head of Antibody Engineering in the Biologics Research Department at Janssen, the pharmaceutical branch of Johnson & Johnson (J&J).

Dr. Chao Han is the Vice President of Early Development and the Site Head of Tavotek Lab at Lower Gwynedd, Pennsylvania. He has more than 20 years of experience in preclinical discovery and clinical development of small molecule and biologic therapeutics. Prior to joining Tavotek, Dr. Han was the Scientific Director of Biologics Development Sciences at Janssen. He has worked at GSK as the DMPK Head and the Section Head of Pharmacokinetics and In Vivo Technology.

Mr. Mark Tornetta is Vice President of Biologics Discovery at Tavotek Biotherapeutics. He has over 29 years of discovery biopharmaceutical experience, 23 years in antibody engineering and 6 years in target discovery working on orphan GPCRs. His biopharma activities involved targets in cardiovascular, pulmonary, metabolic, immune, oncological, and infectious diseases.

Maria P. MacWilliams Ph.D. is Vice President of Molecular Biology at Tavotek Biotherapeutics. Dr. MacWilliams has over 30 years experience with synthetic protein design and development of novel cell based assays. Her scientific career spans many diverse areas of science including protein engineering, structure-function studies of DNA recombinases and nucleases, analyses of small molecule drug complexes, soil metagenomics, and environmental microbiology. Dr. MacWilliams has strong expertise in developing assays to elucidate complex molecular interactions. Dr. MacWilliams obtained her B.S. in Biology with Honors from Saint Joseph’s University (Philadelphia, Pennsylvania) and her Masters and Ph.D. in Microbiology from the University of Illinois Urbana-Champaign. After a short post-doctoral stint during which she established a new research direction for her Ph.D. mentor and a collaborator, she did post-doctoral research at the Biozentrum of the University of Basel (Basel, Switzerland). Dr. MacWilliams held faculty appointments at Seton Hall University and the University of Wisconsin-Parkside. In addition to her major contributions to science education at the college level, she is committed to community outreach programs in support of scientific understanding for all. Dr. MacWilliams is most proud of the 38 masters, undergraduate and high school students she has mentored during her time in academia. After nearly two decades in academia, she transitioned to the pharmaceutical industry, working in antibody engineering and high-throughput screening at Janssen and then developing gene editing techniques to create novel cell-based therapeutics at IO Biosciences. Her publication record includes 14 research articles in high-impact journals as well as several methods articles and numerous scientific meeting presentations.

Dr. Di Zhang is the Vice President of Discovery at Tavotek Biotherapeutics. He has nearly 20 years of experience in new drug discovery for several renowned pharmaceutical companies, including AbbVie/Abbott Laboratories and Janssen. Prior to joining Tavotek, Dr. Zhang was a Senior Investigator in the Biologics Research Department at Janssen, the pharmaceutical branch of Johnson & Johnson (J&J).

Mr. Wei Zhang is the Chief Operations Officer at Tavotek Biotherapeutics. Before joining Tavotek, he was the Head of Digital Health and Information Technology at the Johnson and Johnson (J&J) Asia Pacific Innovation Center. While at J&J, he worked extensively with the global therapeutic team to identify and explore novel ideas and concepts from external partners to facilitate new business opportunities. The scope of his work included Big Data, Artificial Intelligence for drug development, business intelligence, robotic technology, etc. Before his career at J&J, Mr. Zhang was a successful serial entrepreneur and co-founded Chance Share Consultant Company which provided pharmaceutical consulting services to major Big Pharma players such as Bayer, Sanofi, and MSD. He oversaw and managed operational processes to ensure excellent customer experience. In addition, his role at Chance Share included optimizing the company's operating capabilities, business strategies, along with financial policies and procedures. Under his tenure at Chance Share, business grew rapidly and successfully. Prior to his entrepreneurial period, Mr. Zhang was an Information Technology Business Partner of the global conglomerate Unilever for more than 13 years. His role at Unilever included serving as the strategic interface with assigned business units and various functional areas in business technology strategy development, solution discovery, and operation management. He provided important strategic consulting support and advice through various critical Information Technology initiatives for the company. His work at Unilever also included sharingknowledge of technology opportunities to build competitive advantage to improve efficiency and effectiveness of business units. Mr. Zhang has extensive training in Information Technology and received his master’s degree in computer science from Fudan University. His extensive experience in partnering with many business and key stakeholders are invaluable to the success of business operations in Tavotek.

Ms. Susan Tam is Vice President of Discovery Research at Tavotek Biotherapeutics. She has extensive pharmaceutical industrial experience (over 30 years) mainly focused on in vitro diagnostics, and antibody- protein therapeutics. Her diverse research and therapeutic background include oncology, immunology, neuroscience, infectious diseases, cardiovascular and metabolic disease.